December 8, 2025Blood

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

View Full Paper

Ask AI

Bookmark

Authors

OBOndřej Bláha MSMikkael A. SekeresUniversity of Miami HCHetty E. CarrawayCleveland Clinic

Discussion

Member takes

Implication

Analysis reveals that achieving marrow complete remission with hypomethylating agents does not improve overall survival in higher risk MDS, suggesting the need for revised assessment criteria.

Key Points

Median overall survival for marrow complete remission was 16 months, with no improvement compared to non-remitters.
Patients undergoing allogenic stem cell transplantation showed varied outcomes based on previous remission status.
Assessment used Kaplain-Meier methods for overall survival calculations in the icMDS VALIDATE dataset.
Current IWG guidelines should replace older criteria in evaluating treatment response for myelodysplastic syndrome.

Cite This Study

Bláha et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d85b https://doi.org/10.1182/blood-2025-3865

View Full Paper

Ask AI

Bookmark

Implication

Analysis reveals that achieving marrow complete remission with hypomethylating agents does not improve overall survival in higher risk MDS, suggesting the need for revised assessment criteria.

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Discussion

Member takes

Implication

Key Points

Cite This Study

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider